No, focal proliferative glomerulonephritis and focal segmental glomerulosclerosis are distinct entities, though they can be difficult to distinguish when scarring occurs.
Key Distinctions
Focal proliferative glomerulonephritis and focal segmental glomerulosclerosis (FSGS) represent different pathologic processes that should not be conflated. Focal proliferative GN involves endocapillary proliferation (active inflammatory cell proliferation within glomerular capillaries), while FSGS is characterized by segmental sclerosis (scarring) associated with podocyte injury 1, 2.
The Diagnostic Challenge
The confusion arises because scarred focal proliferative GN can become morphologically indistinguishable from FSGS on light microscopy alone 1. A 1978 study analyzing 334 renal biopsies found that:
- When focal proliferative GN heals and scars, it produces segmental sclerotic lesions that mimic FSGS
- Two independent observers could not reliably differentiate scarred focal proliferative GN from FSGS using optical microscopy alone
- Some cases of focal proliferative GN (particularly those without systemic disease and negative immunofluorescence) cannot be distinguished from FSGS even with immunofluorescence and electron microscopy 1
Critical Pathophysiologic Differences
FSGS is fundamentally a podocytopathy - a disease of podocyte injury and loss - not a proliferative process 2, 3. The unifying feature is podocyte damage leading to foot process effacement and subsequent segmental scarring. This can be:
- Primary (circulating permeability factors)
- Secondary (maladaptive response to hyperfiltration, viral, drug-induced)
- Genetic 3
In contrast, focal proliferative GN represents active glomerular inflammation with endocapillary proliferation, typically associated with immune complex deposition or systemic diseases.
Clinical Implications
The distinction matters because:
- Primary FSGS may respond to immunosuppression; secondary and genetic FSGS do not 3
- Scarred focal proliferative GN from resolved inflammation has a different treatment approach than active FSGS
- FSGS tends to recur after transplantation (primary forms), while secondary forms typically do not 3
Common Pitfall
Do not assume all segmental sclerotic lesions represent primary FSGS requiring immunosuppression. The KDIGO 2021 guidelines emphasize the need to differentiate FSGS mediated by soluble factors (potentially amenable to immunosuppression) from conditions with FSGS-like histology where immunosuppression should be avoided 4. This includes recognizing that segmental sclerosis may represent end-stage scarring from a previous proliferative process rather than true podocytopathy.